Total Payments
$451,587
2024 Payments
$9,704
Companies
16
Transactions
523
Medicare Patients
360
Medicare Billing
$52,539
Payment Breakdown by Category
Other$202,634 (44.9%)
Consulting$160,925 (35.6%)
Travel$71,576 (15.8%)
Food & Beverage$9,396 (2.1%)
Research$6,816 (1.5%)
Education$241.02 (0.1%)
Payments by Nature
| Nature of Payment | Amount | Transactions | Share |
|---|---|---|---|
| Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | $202,634 | 72 | 44.9% |
| Consulting Fee | $160,925 | 65 | 35.6% |
| Travel and Lodging | $71,576 | 192 | 15.8% |
| Food and Beverage | $9,396 | 161 | 2.1% |
| Unspecified | $6,816 | 27 | 1.5% |
| Education | $241.02 | 6 | 0.1% |
Payments by Type
General
$444,771
496 transactions
Research
$6,816
27 transactions
Top Paying Companies
| Company | Total | Records | Latest Year |
|---|---|---|---|
| JAZZ PHARMACEUTICALS INC. | $229,989 | 272 | $0 (2024) |
| Merck Sharp & Dohme Corporation | $105,472 | 113 | $0 (2018) |
| Eisai Inc. | $44,935 | 47 | $0 (2020) |
| HARMONY BIOSCIENCES LLC | $38,720 | 34 | $0 (2024) |
| Takeda Pharmaceuticals U.S.A., Inc. | $12,565 | 30 | $0 (2024) |
| Alkermes, Inc. | $5,120 | 3 | $0 (2023) |
| IDORSIA PHARMACEUTICALS US INC | $4,754 | 6 | $0 (2024) |
| SK Life Science, Inc. | $4,200 | 2 | $0 (2020) |
| Sun Pharmaceutical Industries Inc. | $2,515 | 3 | $0 (2017) |
| Avadel CNS Pharmaceuticals, LLC | $1,415 | 6 | $0 (2024) |
Payment History by Year
| Year | Amount | Transactions | Top Company |
|---|---|---|---|
| 2024 | $9,704 | 28 | HARMONY BIOSCIENCES LLC ($8,514) |
| 2023 | $20,102 | 24 | JAZZ PHARMACEUTICALS INC. ($11,630) |
| 2022 | $19,531 | 14 | JAZZ PHARMACEUTICALS INC. ($11,225) |
| 2021 | $31,889 | 18 | HARMONY BIOSCIENCES LLC ($16,850) |
| 2020 | $35,047 | 47 | Jazz Pharmaceuticals Inc. ($10,580) |
| 2019 | $37,167 | 64 | Eisai Inc. ($21,477) |
| 2018 | $58,319 | 58 | Jazz Pharmaceuticals Inc. ($27,870) |
| 2017 | $239,829 | 270 | Jazz Pharmaceuticals Inc. ($147,728) |
All Payment Transactions
523 individual payment records from CMS Open Payments — Page 1 of 21
| Date | Company | Product | Nature | Form | Amount | Type |
|---|---|---|---|---|---|---|
| 12/19/2024 | IDORSIA PHARMACEUTICALS US INC | QUVIVIQ (Drug) | Food and Beverage | In-kind items and services | $24.96 | General |
| Category: Insomnia | ||||||
| 12/13/2024 | HARMONY BIOSCIENCES LLC | WAKIX (Drug) | Consulting Fee | Cash or cash equivalent | $1,725.00 | General |
| Category: Narcoplepsy | ||||||
| 12/12/2024 | HARMONY BIOSCIENCES LLC | WAKIX (Drug) | Consulting Fee | Cash or cash equivalent | $781.50 | General |
| Category: Narcoplepsy | ||||||
| 11/21/2024 | JAZZ PHARMACEUTICALS INC. | XYWAV (Drug) | Food and Beverage | In-kind items and services | $28.45 | General |
| Category: NEUROLOGY | ||||||
| 10/23/2024 | HARMONY BIOSCIENCES LLC | WAKIX (Drug) | — | Cash or cash equivalent | $1,500.00 | Research |
| Study: WAKIX (Pitolisant) Pregnancy Registry: An Observational Study of the Safety of Pitolisant Exposure in Pregnant Women and Their Offspring • Category: Narcoplepsy | ||||||
| 10/16/2024 | HARMONY BIOSCIENCES LLC | WAKIX (Drug) | Consulting Fee | Cash or cash equivalent | $781.50 | General |
| Category: Narcoplepsy | ||||||
| 09/26/2024 | Avadel CNS Pharmaceuticals, LLC | — | Food and Beverage | In-kind items and services | $49.39 | General |
| 09/25/2024 | Axsome Therapeutics, Inc. | — | Food and Beverage | In-kind items and services | $43.48 | General |
| 09/12/2024 | HARMONY BIOSCIENCES LLC | WAKIX (Drug) | Food and Beverage | Cash or cash equivalent | $5.09 | General |
| Category: Narcoplepsy | ||||||
| 09/06/2024 | HARMONY BIOSCIENCES LLC | WAKIX (Drug) | Food and Beverage | Cash or cash equivalent | $11.06 | General |
| Category: Narcoplepsy | ||||||
| 09/06/2024 | HARMONY BIOSCIENCES LLC | WAKIX (Drug) | Food and Beverage | Cash or cash equivalent | $0.76 | General |
| Category: Narcoplepsy | ||||||
| 08/23/2024 | HARMONY BIOSCIENCES LLC | WAKIX (Drug) | Food and Beverage | Cash or cash equivalent | $12.56 | General |
| Category: Narcoplepsy | ||||||
| 08/22/2024 | Avadel CNS Pharmaceuticals, LLC | LUMRYZ (Drug) | Food and Beverage | In-kind items and services | $23.53 | General |
| Category: CENTRAL NERVOUS SYSTEM CNS NEUROLOGY | ||||||
| 08/15/2024 | HARMONY BIOSCIENCES LLC | WAKIX (Drug) | Food and Beverage | Cash or cash equivalent | $14.24 | General |
| Category: Narcoplepsy | ||||||
| 08/15/2024 | HARMONY BIOSCIENCES LLC | WAKIX (Drug) | Food and Beverage | Cash or cash equivalent | $4.57 | General |
| Category: Narcoplepsy | ||||||
| 08/08/2024 | HARMONY BIOSCIENCES LLC | WAKIX (Drug) | Food and Beverage | Cash or cash equivalent | $12.58 | General |
| Category: Narcoplepsy | ||||||
| 06/05/2024 | Avadel CNS Pharmaceuticals, LLC | LUMRYZ (Drug) | Consulting Fee | Cash or cash equivalent | $450.00 | General |
| Category: CENTRAL NERVOUS SYSTEM CNS NEUROLOGY | ||||||
| 06/02/2024 | JAZZ PHARMACEUTICALS INC. | XYREM (Drug) | Food and Beverage | In-kind items and services | $182.83 | General |
| Category: NEUROLOGY | ||||||
| 06/01/2024 | Takeda Pharmaceuticals U.S.A., Inc. | — | Food and Beverage | In-kind items and services | $46.97 | General |
| 05/17/2024 | HARMONY BIOSCIENCES LLC | WAKIX (Drug) | Consulting Fee | Cash or cash equivalent | $781.50 | General |
| Category: Narcoplepsy | ||||||
| 05/17/2024 | HARMONY BIOSCIENCES LLC | WAKIX (Drug) | Consulting Fee | Cash or cash equivalent | $781.50 | General |
| Category: Narcoplepsy | ||||||
| 04/24/2024 | HARMONY BIOSCIENCES LLC | WAKIX (Drug) | Food and Beverage | Cash or cash equivalent | $6.77 | General |
| Category: Narcoplepsy | ||||||
| 04/16/2024 | Avadel CNS Pharmaceuticals, LLC | LUMRYZ (Drug) | Food and Beverage | In-kind items and services | $104.57 | General |
| Category: CENTRAL NERVOUS SYSTEM CNS NEUROLOGY | ||||||
| 04/11/2024 | HARMONY BIOSCIENCES LLC | WAKIX (Drug) | Consulting Fee | Cash or cash equivalent | $2,084.00 | General |
| Category: Narcoplepsy | ||||||
| 04/03/2024 | Avadel CNS Pharmaceuticals, LLC | LUMRYZ (Drug) | Consulting Fee | Cash or cash equivalent | $225.00 | General |
| Category: CENTRAL NERVOUS SYSTEM CNS NEUROLOGY | ||||||
Research Studies & Clinical Trials
| Study Name | Company | Amount | Records |
|---|---|---|---|
| A RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED, MULTIPLE RISING ORAL DOSE STUDY TO EVALUATE THE SAFETY, TOLERABILITY, PHARMACOKINETICS, AND PHARMACODYNAMICS OF TAK-994 IN PATIENTS WITH NARCOLEPSY WITH OR WITHOUT CATAPLEXY (NARCOLEPSY TYPE 1 OR NARCOLEPSY TYPE 2) | Takeda Pharmaceuticals U.S.A., Inc. | $2,522 | 19 |
| TAK-994: RESEARCH ACTIVITIES ACROSS OREXIN PROGRAM | Takeda Pharmaceuticals U.S.A., Inc. | $2,453 | 1 |
| WAKIX (Pitolisant) Pregnancy Registry: An Observational Study of the Safety of Pitolisant Exposure in Pregnant Women and Their Offspring | HARMONY BIOSCIENCES LLC | $1,500 | 1 |
| A STUDY TO ASSESS THE FREQUENCY AND CHARACTERISTICS OF WAKE AND SLEEP STATE TRANSITIONS OVER MULTIPLE NIGHTS IN SUBJECTS WITH NARCOLEPSY TYPE 1 COMPARED WITH HEALTHY SUBJECTS USING A PORTABLE ELECTROENCEPHALOGRAM DEVICE | Takeda Pharmaceuticals U.S.A., Inc. | $261.26 | 5 |
| A Multicenter Study of the Efficacy and Safety of JZP-258 in the Treatment of Idiopathic Hypersomnia IH With an Open-label Safety Extension | Jazz Pharmaceuticals Inc. | $80.43 | 1 |
Medicare Billing by Year
| Year | Procedures | Beneficiaries | Services | Submitted | Medicare Paid |
|---|---|---|---|---|---|
| 2023 | 3 | 116 | 180 | $122,525 | $20,062 |
| 2022 | 3 | 99 | 136 | $89,750 | $15,347 |
| 2021 | 4 | 74 | 103 | $56,435 | $10,029 |
| 2020 | 3 | 71 | 103 | $39,450 | $7,102 |
Total Patients
360
Total Services
522
Medicare Billing
$52,539
Procedure Codes
13
All Medicare Procedures & Services
13 procedure records from CMS Medicare Utilization
| HCPCS | Description | Setting | Year | Patients | Services | Charges | Medicare Paid | Ratio |
|---|---|---|---|---|---|---|---|---|
| 99214 | Established patient office or other outpatient visit, 30-39 minutes | Office | 2023 | 76 | 138 | $89,700 | $15,058 | 16.8% |
| 99204 | New patient office or other outpatient visit, 45-59 minutes | Office | 2023 | 27 | 27 | $25,095 | $3,725 | 14.8% |
| 99213 | Established patient office or other outpatient visit, 20-29 minutes | Office | 2023 | 13 | 15 | $7,730 | $1,279 | 16.6% |
| 99214 | Established patient office or other outpatient visit, 30-39 minutes | Office | 2022 | 52 | 84 | $54,600 | $9,349 | 17.1% |
| 99204 | New patient office or other outpatient visit, 45-59 minutes | Office | 2022 | 25 | 25 | $23,000 | $3,896 | 16.9% |
| 99213 | Established patient office or other outpatient visit, 20-29 minutes | Office | 2022 | 22 | 27 | $12,150 | $2,102 | 17.3% |
| 99214 | Established patient outpatient visit, total time 30-39 minutes | Office | 2021 | 28 | 42 | $26,040 | $4,463 | 17.1% |
| 99443 | Physician telephone patient service, 21-30 minutes of medical discussion | Office | 2021 | 17 | 23 | $14,325 | $2,811 | 19.6% |
| 99213 | Established patient outpatient visit, total time 20-29 minutes | Office | 2021 | 15 | 20 | $9,000 | $1,585 | 17.6% |
| 99442 | Physician telephone patient service, 11-20 minutes of medical discussion | Office | 2021 | 14 | 18 | $7,070 | $1,171 | 16.6% |
| 99442 | Physician telephone patient service, 11-20 minutes of medical discussion | Office | 2020 | 29 | 51 | $14,530 | $3,659 | 25.2% |
| 99214 | Established patient office or other outpatient, visit typically 25 minutes | Office | 2020 | 21 | 29 | $14,790 | $1,847 | 12.5% |
| 99213 | Established patient office or other outpatient visit, typically 15 minutes | Office | 2020 | 21 | 23 | $10,130 | $1,596 | 15.8% |
About Dr. Michael Thorpy, MD
Dr. Michael Thorpy, MD is a Neurology healthcare provider based in Bronx, New York. This provider has been registered with the National Plan and Provider Enumeration System (NPPES) since 10/26/2006. The National Provider Identifier (NPI) number assigned to this provider is 1134204456.
According to the Centers for Medicare & Medicaid Services (CMS) Open Payments database, Dr. Michael Thorpy, MD has received a total of $451,587 in payments from pharmaceutical and medical device companies, with $9,704 received in 2024. These payments were reported across 523 transactions from 16 companies. The most common payment nature is "Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program" ($202,634).
As a Medicare-enrolled provider, Thorpy has provided services to 360 Medicare beneficiaries, totaling 522 services with total Medicare billing of $52,539. Data is available for 4 years (2020–2023), covering 13 distinct procedure/service records.
Ad
Practice Information
- Specialty Neurology
- Location Bronx, NY
- Active Since 10/26/2006
- Last Updated 07/08/2007
- Taxonomy Code 2084N0400X
- Entity Type Individual
- NPI Number 1134204456
Products in Payments
- Xyrem (Drug) $149,593
- BELSOMRA (Drug) $105,472
- Wakix (Drug) $24,807
- XYWAV (Drug) $19,665
- XYREM (Drug) $13,378
- SUNOSI (Drug) $8,961
- WAKIX (Drug) $8,514
- QUVIVIQ (Drug) $4,754
- Cenobamate (Drug) $4,200
- Odomzo (Drug) $2,515
- Dayvigo (Drug) $2,400
- LUMRYZ (Drug) $1,366
- Defitelio (Drug) $800.00
- Noctiva (Drug) $259.16
- ORENITRAM (Drug) $35.15
- Hetlioz (Drug) $21.53
Data Sources
Provider data from NPPES. Payment data from CMS Open Payments. Medicare data from CMS Medicare Provider Utilization. All data is public and updated periodically.
Neurology Doctors in Bronx
Richard Lipton, Md, MD
Neurology — Payments: $982,914
Neurology $982,914
Rene Elkin, Md, MD
Neurology — Payments: $343,327
Neurology $343,327
Jelena Pavlovic, M.d, M.D
Neurology — Payments: $130,235
Neurology $130,235
Dr. Sandeep Gulati, D.o, D.O
Neurology — Payments: $124,853
Neurology $124,853
Dr. Lauren Gluck, Md, MD
Neurology — Payments: $53,848
Neurology $53,848
Christopher Langston
Neurology — Payments: $46,700
Neurology $46,700